PRESS RELEASE · Development Update
Release date
TFA-01
The formulation will be injected into dogs with osteoarthritis to evaluate its effects and safety
On October 7, 2026, TFA Therapeutics, Inc. received the TFA-01 injectable nanoformulation from the research teams of Professor Hsian-Yu Wang of the Graduate Institute of Animal Vaccine Technology and Assistant Professor Wei-Yu Chen of the Functional Materials and Analytical Technology Laboratory in the Department of Materials Engineering. Each vial contains 5 mL (5 cc) at a concentration of 150 ppm. The formulation will be supplied to the clinical team in Shanghai for a canine osteoarthritis clinical trial.
The formulation will be administered by injection to dogs with osteoarthritis to observe and evaluate its effects and safety following administration. This delivery connects the development of the nanoformulation with trials involving administration to dogs, marking a concrete step in the TFA-01 development program.
The aim of developing the injectable nanoformulation is to help the body use Antcin A more efficiently, with the potential to more fully realize its anti-inflammatory activity. Through formulation design, the research teams aim to improve the dispersion of the active ingredient and drug release, and to identify a suitable injection dose and duration of action.
For pets and their owners, extending the interval between doses while maintaining therapeutic effects could reduce the need for repeated injections, ease the burden of care, and make ongoing treatment more convenient. This is an important current research direction for the TFA-01 injectable nanoformulation.
TFA-01 is being developed with canine osteoarthritis as its first indication. TFA continues to advance a new anti-inflammatory drug with the potential to serve as an alternative to corticosteroids, aiming for a future product that combines efficacy, safety, and convenience.
About TFA
TFA Therapeutics, Inc. (OTCQB: RAJAF) is developing TFA-01, an Antcin A-based drug candidate, with canine osteoarthritis as its initial target indication. The program includes source material and formulation development, as well as safety and efficacy evaluation.
Forward-looking statements: The development plans described in this release may change in response to study results, regulatory requirements, and funding arrangements. Actual progress and outcomes may differ from current expectations.